Clinical Trial Failure
The latest news about Clinical Trial Failure: headlines, AI summaries and the full story from every source.
- EyePoint Pharmaceuticals Announces Strategic Shift to DURAVYU DME Following Phase III Wet AMD Trial Failures
- Pomerantz Law Firm Investigates Potential Securities Fraud at Foghorn Therapeutics (FHTX)
- Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro (CLPT)
- Pomerantz Law Firm Investigates Artiva Biotherapeutics Following Program Discontinuation and Fatal Safety Events
- Novartis to Halt Development of Ionis-Derived Heart Disease Therapy Following Clinical Trial Failure
- Pomerantz Law Firm Investigates Rafael Holdings Following Failed Phase 3 Clinical Trial
- Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
- Pomerantz Law Firm Investigates Syndax Pharmaceuticals Following Failed Phase 2 Clinical Trial
- Pomerantz Law Firm Investigates argenx SE Following Discontinuation of Phase 3 Sjögren's Disease Study
- Berger Montague Announces Class Action Lawsuit Against Tenax Therapeutics Following Phase 3 Trial Failure
- Acumen Pharmaceuticals Shares Plunge Following Failed Alzheimer's Clinical Trial
- Pomerantz Law Firm Investigates Rafael Holdings Following Failed Phase 3 Clinical Trial
- Pomerantz Law Firm Investigates Foghorn Therapeutics Following Clinical Program Termination and Workforce Reduction
- Pomerantz Law Firm Investigates Potential Securities Fraud at ClearPoint Neuro, Inc.
- Pomerantz Law Firm Investigates EyePoint, Inc. Following Clinical Trial Failures
- Novartis Suffers Third Drug Trial Setback in a Week and Faces Worst Trading Day in Years
- Novartis (NVS) and Ionis (IONS)' Experimental Cholesterol Drug Fails in Late-Stage Trial
- AstraZeneca's Breast Cancer Drug Fails Late-Stage Trial, Citi Maintains 'Buy' Rating
- BofA Sees Limited Impact from Novartis’ Pelacarsen Trial Failure, Citi Eyes Ionis
- Dow Jones Falls Sharply Due to Novartis' Failed Drug Trials
- Novartis, Boston Scientific Shares Decline; Intel Rises Amid Price Hike Report
- Ionis Pharmaceuticals' Sell-Off Was Overdone Despite Clinical Setbacks
- Novo Nordisk Shares Drop After Key Trial Failure
- Novo Nordisk Shares Drop After Late-Stage Trial Failure
- AstraZeneca Faces Securities Fraud Investigation Following Failed Clinical Trial
- Investor Alert: Pomerantz Law Firm Investigates Ionis Pharmaceuticals for Potential Securities Fraud
- Trevi Shares Rise Following GSK's Discontinuation of Chronic Cough Therapy
- Investor Alert: Pomerantz Law Firm Investigates Ionis Pharmaceuticals for Potential Securities Fraud
- Ionis Pharmaceuticals Shares Drop Amid Failed Clinical Trial and Roche Partnership Exit
- Pomerantz Law Firm Investigates Valneva SE for Potential Securities Fraud
- Pomerantz Law Firm Investigates Theravance Biopharma for Potential Securities Fraud